R&D Closed & Collaborative H2 2025: Mergers, acquisitions, partn... The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.
News Gilead strikes deal to expand HIV drug access in 120 countri... Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free
Market Access SteinCares and Sandoz: Bringing high-quality healthcare prod... Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.